Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 88

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Encephalitis autoimmune

Not recruiting

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Not recruiting

Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Multiple system atrophy

Not recruiting

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Takeda Development Center Americas Inc.

Duchenne muscular dystrophy

Not recruiting

Study on the Effects of Satralizumab in Children and Adolescents with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Sponsor:F. Hoffmann-La Roche AG

Neuromyelitis optica spectrum disorder

Not recruiting

Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Encephalopathy neonatal+1

Not recruiting

Study on the Effect of Allopurinol and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Allopurinol Sodium
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Hepato-lenticular degeneration

Not recruiting

Study of Trientine Dihydrochloride (Cufence) to Evaluate Its Effects and Safety in Patients with Wilson's Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Trientine Dihydrochloride
  • Sponsor:Univar Solutions B.V.

Multiple sclerosis

Not recruiting

Study on Amantadine and Transcranial Magnetic Stimulation for Reducing Fatigue in Multiple Sclerosis Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amantadine Hydrochloride
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos

Progressive supranuclear palsy

Not recruiting

Study of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt
  • Sponsor:Ferrer Internacional S.A.

Aicardi-Goutieres syndrome

Not recruiting

Study on the Safety of Censavudine (TPN-101) for Patients with Aicardi-Goutières Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Censavudine
  • Sponsor:Transposon Therapeutics Inc.

Fabry's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Pegunigalsidase Alfa for Adults with Fabry Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Pegunigalsidase Alfa
  • Sponsor:Chiesi Farmaceutici S.p.A.

Human herpesvirus 6 encephalitis

Not recruiting

Study on Dexamethasone for Patients with Herpes Simplex Virus Encephalitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.